| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
16 September 2003 | Volume 139 Issue 6 | Pages 483-487
Background: Antibiotic treatment selects for resistance not only in the pathogen to which it is directed but also in the indigenous microflora.
Objective: To determine whether a widely used regimen (clarithromycin, metronidazole, and omeprazole) for Helicobacter pylori eradication affects resistance development in enterococci.
Design: Cohort study.
Setting: Endoscopy units at 3 community hospitals in Sweden.
Patients: 5 consecutive dyspeptic patients who were colonized with H. pylori, had endoscopy-confirmed duodenal ulcer, and received antibiotic treatment, and 5 consecutive controls with dyspepsia but no ulcer who did not receive treatment.
Measurements: Fecal samples were obtained from patients and controls before, immediately after, 1 year after, and 3 years after treatment. From each patient and sample, enterococci were isolated and analyzed for DNA fingerprint, clarithromycin susceptibility, and presence of the erm(B) gene.
Results: In treated patients, all enterococci isolated immediately after treatment showed high-level clarithromycin resistance due to erm(B). In 3 patients, resistant enterococci persisted for 1 to 3 years after treatment. No resistance developed among controls.
Conclusion: A common H. pylori treatment selects for highly resistant enterococci that can persist for at least 3 years without further selection.
Editors' Notes
Context
Contribution
Implications
The Editors
Author and Article Information
From University Hospital Uppsala, Uppsala, and The Swedish Institute for Infectious Disease Control, Solna, Sweden; and New York University School of Medicine, New York, New York.
Acknowledgments: The authors thank Lena Zimmergren for coordinating the collection of samples and Lena Eriksson and Kristina Schönmeyr for excellent technical assistance.
Grant Support: By the AFA Health Research Foundation, Stockholm, Sweden, and by the National Institutes of Health (RO1GM63270).
Potential Financial Conflicts of Interest: None disclosed.
Requests for Single Reprints: Lars Engstrand, MD, Department of Bacteriology, Swedish Institute for Infectious Disease Control, SE-171 82 Solna, Sweden; e-mail, lars.engstrand{at}smi.ki.se.
Current Author Addresses: Ms. Sjölund: Department of Medical Sciences, Clinical Bacteriology, University Hospital Uppsala, Box 552, SE-751 22 Uppsala, Sweden.
Ms. Wreiber and Drs. Andersson and Engstrand: Department of Bacteriology, Swedish Institute for Infectious Disease Control, SE-171 82 Solna, Sweden.
Dr. Blaser: Departments of Medicine and Microbiology, New York University School of Medicine, New York, NY 10016.
Author Contributions: Conception and design: M. Sjölund, L. Engstrand.
Analysis and interpretation of the data: M. Sjölund, D.I. Andersson, M.J. Blaser, L. Engstrand.
Drafting of the article: M. Sjölund, D.I. Andersson, M.J. Blaser, L. Engstrand.
Critical revision of the article for important intellectual content: M. Sjölund, D.I. Andersson, M.J. Blaser, L. Engstrand.
Final approval of the article: M. Sjölund, K. Wreiber, D.I. Andersson, M.J. Blaser, L. Engstrand.
Provision of study materials or patients: K. Wreiber.
Obtaining of funding: L. Engstrand.
Administrative, technical, or logistic support: K. Wreiber, L. Engstrand.
Collection and assembly of data: K. Wreiber, L. Engstrand. BRIEF COMMUNICATION
Long-Term Persistence of Resistant Enterococcus Species after Antibiotics To Eradicate Helicobacter pylori
![]()
![]()
Related articles in Annals:
This article has been cited by other articles:
![]() |
Y.-C. Lee, J.-M. Liou, C.-Y. Wu, and J.-T. Lin Review: Eradication of Helicobacter pylori to prevent gastroduodenal diseases: Hitting more than one bird with the same stone Therapeutic Advances in Gastroenterology, September 1, 2008; 1(2): 111 - 120. [Abstract] [PDF] |
||||
![]() |
F. Francois and M. J. Blaser Improving Helicobacter pylori Eradication Regimens Ann Intern Med, January 17, 2006; 144(2): 140 - 141. [Full Text] [PDF] |
||||
![]() |
D I Campbell and J E Thomas Helicobacter pylori infection in paediatric practice Arch. Dis. Child. Ed. Pract., August 1, 2005; 90(2): ep25 - ep30. [Full Text] [PDF] |
||||
![]() |
D. H. Mariam, Y. Mengistu, S. E. Hoffner, and D. I. Andersson Effect of rpoB Mutations Conferring Rifampin Resistance on Fitness of Mycobacterium tuberculosis Antimicrob. Agents Chemother., April 1, 2004; 48(4): 1289 - 1294. [Abstract] [Full Text] [PDF] |
||||
![]() |
JournalScan Gut, February 1, 2004; 53(2): 314 - 314. [Full Text] [PDF] |
||||
![]() |
H. pylori Treatment Resistance Journal Watch Dermatology, November 26, 2003; 2003(1126): 9 - 9. [Full Text] |
||||
![]() |
H. pylori Treatment Resistance Journal Watch (General), October 14, 2003; 2003(1014): 4 - 4. [Full Text] |
||||
![]() |
L. B. Rice Collateral Damage Ann Intern Med, September 16, 2003; 139(6): 523 - 524. [Full Text] [PDF] |
||||